Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis and Novel transaction has been resolved amicably to the satisfaction of all parties.

Shares of Lupin were trading 2.5 per cent higher at Rs 985 on the BSE on Thursday after the pharmaceutical company settled a dispute with Gavis Pharma and Novel Laboratories. The stock was trading higher for the fourth straight day, up 5 per cent during the same period.

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis/Novel transaction has been resolved amicably to the satisfaction of all parties. READ HERE

In the past one month, the stock has outperformed the market by gaining 11 per cent, as compared to a